These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The development of molecular vaccines against malaria sporozoites. Ballou WR, Young JF, Cryz SJ, Sadoff JC. Adv Exp Med Biol; 1989; 251():295-313. PubMed ID: 2692428 [No Abstract] [Full Text] [Related]
5. Vaccines for human malaria: epidemiological and immunological perspectives. Webster HK, Diggs CL, Ballou WR, Chulay JD. Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):375-89. PubMed ID: 3064321 [No Abstract] [Full Text] [Related]
6. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. Etlinger HM, Felix AM, Gillessen D, Heimer EP, Just M, Pink JR, Sinigaglia F, Stürchler D, Takacs B, Trzeciak A. J Immunol; 1988 Jan 15; 140(2):626-33. PubMed ID: 3275719 [Abstract] [Full Text] [Related]
10. Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax. Lowell GH, Ballou WR, Smith LF, Zollinger WD, Hockmeyer WT. Trans R Soc Trop Med Hyg; 1989 Jan 15; 83 Suppl():101-2. PubMed ID: 2696152 [Abstract] [Full Text] [Related]
12. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity. Dobaño C, Sedegah M, Rogers WO, Kumar S, Zheng H, Hoffman SL, Doolan DL. Exp Parasitol; 2009 Jun 15; 122(2):112-23. PubMed ID: 19249301 [Abstract] [Full Text] [Related]
13. Parasitology. Malaria--from infants to genomics to vaccines. Long CA, Hoffman SL. Science; 2002 Jul 19; 297(5580):345-7. PubMed ID: 12130768 [No Abstract] [Full Text] [Related]
15. Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum. Etlinger HM, Heimer EP, Trzeciak A, Felix AM, Gillessen D. Immunology; 1988 Jul 19; 64(3):551-8. PubMed ID: 3044983 [Abstract] [Full Text] [Related]
16. Development of asexual blood stage malaria vaccines. Kidson C. Southeast Asian J Trop Med Public Health; 1988 Sep 19; 19(3):391-6. PubMed ID: 3064322 [No Abstract] [Full Text] [Related]
19. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, Tanner M, Alonso P, Nebie I, Romero JF, Silvie O, Torgler R, Corradin G. Vaccine; 2009 Jan 07; 27(2):328-35. PubMed ID: 18984024 [Abstract] [Full Text] [Related]
20. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Patarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, Martínez A, Rodríguez R, Guzman F, Cabezas E. Nature; 2009 Jan 07; 328(6131):629-32. PubMed ID: 3302727 [Abstract] [Full Text] [Related] Page: [Next] [New Search]